BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 28, 2010
 |  BioCentury  |  Strategy

Sosei's Consolidation Play

Sosei plays consolidator in Japan biotech by acquiring Activus

Japanese biotech and pharma companies, including Sosei Group Corp., have tended to build their businesses by acquiring foreign assets. Sosei's acquisition of Activus Pharma Co. Ltd., a Japanese nanoparticle-based formulation company, breaks the mold. The move reaffirms Sosei's reprofiling strategy and may throw light on how investors view consolidation within the Japanese biotech sector.

Sosei's business model is to find new indications for old drugs. In 2005, it acquired U.K. reprofiler Arakis Ltd., which provided the technology that now underpins glycopyrronium bromide (NVA237), an inhaled muscarinic receptor antagonist being co-developed in collaboration with Vectura Group plc. Novartis AG has rights to NVA237 from Vectura and Sosei under a 2005 deal (see BioCentury, April 18, & July 25, 2005).

NVA237 is in Phase III trials to treat chronic obstructive pulmonary...

Read the full 659 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >